Status:

COMPLETED

14C-ARN-509 Microtracer Label AME and Absolute BA Study

Lead Sponsor:

Aragon Pharmaceuticals, Inc.

Conditions:

Healthy

Eligibility:

MALE

50-80 years

Phase:

PHASE1

Brief Summary

This is study in healthy human volunteers to determine the absorption, metabolism, and excretion (AME) profile of ARN-509 as well as its absolute oral bioavailability (BA).

Detailed Description

Two cohorts of 6 healthy volunteers will be enrolled for the AME and absolute BA parts, respectively. The dose for both cohorts is 240 mg. The expected exposure of the dose is 7-fold lower than the st...

Eligibility Criteria

Inclusion

  • Key
  • Gender : male
  • Age : 50 - 80 years, inclusive
  • Body Mass Index (BMI) : 18.5-30.0 kg/m2
  • Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, "power drinks"), grapefruit (juice) and tobacco products from 48 h prior to entry in the clinical research center until discharge
  • Medical history without major pathology
  • Key

Exclusion

  • Evidence of clinically relevant pathology.
  • Mental handicap.
  • History of relevant drug and/or food allergies.
  • Regular/routine treatment with non-topical medications within 30 days prior to entry into the clinical research center.
  • Smoking.
  • History of alcohol abuse or drug addiction (including soft drugs like cannabis products).
  • Use of concomitant medication, except for acetaminophen (paracetamol) and topical medications
  • Irregular defecation pattern (less than once per 2 days).
  • Positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, and alcohol).
  • Intake of more than 24 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits).
  • Positive screen on HBsAg, anti-HCV or anti-HIV 1/2.
  • Illness within five days prior to drug administration.

Key Trial Info

Start Date :

March 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2013

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT01822041

Start Date

March 1 2013

End Date

June 1 2013

Last Update

September 13 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

PRA - Clinical Research Unit, University Medical Centre Groningen

Groningen, Netherlands